Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant

Cancers, Free Full-Text

Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?

Nivolumab Combined With Ipilimumab Shows Activity in Prostate Cancer Subsets - The ASCO Post

Randomised phase II trial of stereotactic body radiotherapy in combination with checkpoint inhibitors in metastatic castration-resistant prostate cancer (CheckPRO): a study protocol

PDF) A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma

Immunotherapy in Cervical and Endometrial Cancers - The ASCO Post

Nivolumab plus ipilimumab, with or without enzalutamide, in AR‐V7‐expressing metastatic castration‐resistant prostate cancer: A phase‐2 nonrandomized clinical trial - Shenderov - 2021 - The Prostate - Wiley Online Library

Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment

Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial - The Lancet Oncology